| abstract |
The invention includes a PRLR-binding protein. In particular, the present invention relates to antibodies, which are chimeric, CDR-grafted, and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. The antibody of the present invention may be a full-length antibody or an antigen-binding portion thereof. Methods of making and using the antibodies of the invention are also provided. The antibodies or antibody portions of the invention are suitable for detecting hPRLR and inhibiting hPRLR activity, for example, in a human individual suffering from a condition in which hPRLR activity is detrimental. The invention also includes anti-PRLR antibody drug conjugates (ADC). |